Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q1 2023 · 10-Q
Revenue$122.18M$122.18M−11.2% vs Q1 2022 Net Income-$53.06M-$53.06MN/M vs Q1 2022 EPS Diluted-$0.50-$0.50N/M vs Q1 2022 Gross Profit$92,568,000−15.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow-$16,727,000N/M Free Cash Flowderived-$22,815,000N/M Margins · derivedGross margin75.8%−4.1 pt vs Q1 2022
Operating margin-49.3%−48.7 pt vs Q1 2022
Net margin-43.4%−40.0 pt vs Q1 2022
ended Mar 31, 2023 · filed May 4, 2023 · 34 d after period end